Tirzepatide is linked to lower risk of major heart events
After balancing the groups’ measured characteristics, estimated one-year risks were 2.9% with tirzepatide versus 4.4% with sitagliptin for heart attack, stroke or death.After balancing the groups’ measured characteristics, estimated one-year risks were 2.9% with tirzepatide versus 4.4% with sitagliptin for heart attack, stroke or death.